The Connected Drug Delivery Devices Market was valued at USD 491.2 million in 2024, and is projected to reach USD 7.25 billion by 2034, rising at a CAGR of 31.8%. These devices integrate modern technology, such as Bluetooth, Wi-Fi, and the Internet of Things (IoT), to improve medication management and administration. They include smart inhalers, insulin pens, wearable injectors, and intelligent pill dispensers, all designed to monitor medication usage, enhance adherence, and enable real-time communication between patients and healthcare providers. The rising incidence of chronic conditions, including asthma, diabetes, and cardiovascular diseases, is fueling demand for these advanced drug delivery systems. Poor medication adherence is a persistent issue in healthcare, leading to higher costs and suboptimal patient outcomes. Connected drug delivery devices help address these concerns by ensuring proper medication intake, streamlining disease management, and reducing hospital visits.
The market is segmented based on device type into connected sensors and integrated devices. Integrated devices accounted for the largest revenue share of 60.9% in 2024. These devices, equipped with reminders, tracking features, and real-time data-sharing capabilities, significantly improve patient compliance with treatment plans. The ability to monitor medication intake remotely has strengthened their adoption across healthcare settings. The increasing prevalence of chronic illnesses has further amplified the demand for integrated drug delivery solutions.
Based on technology, the market is divided into Bluetooth, near field communication, and Wi-Fi. The Bluetooth segment held the highest revenue share of 47.7% in 2024. Low power consumption, affordability, and seamless integration with mobile health applications have driven the widespread adoption of Bluetooth-enabled drug delivery devices. These devices facilitate real-time data exchange between patients and healthcare providers, supporting remote monitoring and digital health platforms. With the rising incidence of chronic diseases, Bluetooth-enabled smart inhalers, insulin pens, and autoinjectors are witnessing increased demand. Additionally, growing investments by pharmaceutical and MedTech companies in Bluetooth-based biosensors and wearable injectors are strengthening market expansion.
By application, the market is categorized into anaphylaxis, respiratory, cardiovascular, diabetes, hormone replacement, and other uses. The respiratory segment generated the highest revenue of USD 221 million in 2024. The increasing burden of asthma, chronic obstructive pulmonary disease (COPD), and other respiratory disorders has amplified the need for connected drug delivery solutions. These devices not only improve treatment adherence but also support remote patient monitoring, strengthening the expansion of telehealth services.
The market is also segmented by end use into hospitals, clinics, home care settings, and others. The home care segment led with USD 198.5 million in revenue in 2024. The growing preference for home-based healthcare, driven by an aging population and the rising need for chronic disease management, has fueled demand for connected drug delivery systems. These devices enable self-administration and remote monitoring, allowing patients to manage their conditions more efficiently.
The U.S. connected drug delivery devices market is projected to grow significantly from USD 156 million in 2023 to USD 2.7 billion by 2034. The increasing adoption of telehealth services, particularly after the COVID-19 pandemic, has accelerated the deployment of connected devices for remote healthcare monitoring.
This product will be delivered within 2-4 business days.
The market is segmented based on device type into connected sensors and integrated devices. Integrated devices accounted for the largest revenue share of 60.9% in 2024. These devices, equipped with reminders, tracking features, and real-time data-sharing capabilities, significantly improve patient compliance with treatment plans. The ability to monitor medication intake remotely has strengthened their adoption across healthcare settings. The increasing prevalence of chronic illnesses has further amplified the demand for integrated drug delivery solutions.
Based on technology, the market is divided into Bluetooth, near field communication, and Wi-Fi. The Bluetooth segment held the highest revenue share of 47.7% in 2024. Low power consumption, affordability, and seamless integration with mobile health applications have driven the widespread adoption of Bluetooth-enabled drug delivery devices. These devices facilitate real-time data exchange between patients and healthcare providers, supporting remote monitoring and digital health platforms. With the rising incidence of chronic diseases, Bluetooth-enabled smart inhalers, insulin pens, and autoinjectors are witnessing increased demand. Additionally, growing investments by pharmaceutical and MedTech companies in Bluetooth-based biosensors and wearable injectors are strengthening market expansion.
By application, the market is categorized into anaphylaxis, respiratory, cardiovascular, diabetes, hormone replacement, and other uses. The respiratory segment generated the highest revenue of USD 221 million in 2024. The increasing burden of asthma, chronic obstructive pulmonary disease (COPD), and other respiratory disorders has amplified the need for connected drug delivery solutions. These devices not only improve treatment adherence but also support remote patient monitoring, strengthening the expansion of telehealth services.
The market is also segmented by end use into hospitals, clinics, home care settings, and others. The home care segment led with USD 198.5 million in revenue in 2024. The growing preference for home-based healthcare, driven by an aging population and the rising need for chronic disease management, has fueled demand for connected drug delivery systems. These devices enable self-administration and remote monitoring, allowing patients to manage their conditions more efficiently.
The U.S. connected drug delivery devices market is projected to grow significantly from USD 156 million in 2023 to USD 2.7 billion by 2034. The increasing adoption of telehealth services, particularly after the COVID-19 pandemic, has accelerated the deployment of connected devices for remote healthcare monitoring.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Device Type, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Technology, 2021-2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)
Chapter 8 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)
Chapter 9 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)
Chapter 10 Company Profiles
Companies Mentioned
The companies featured in this Connected Drug Delivery Devices market report include:- Adherium
- Aptar Pharma
- AstraZeneca
- Becton, Dickinson
- and Company
- Bigfoot Biomedical
- Cohero Health
- Eli Lilly and Company
- Insulet Corporation
- Novartis
- Novo Nordisk
- Phillips Medisize
- Propeller Health
- Teva Pharmaceuticals
- West Pharmaceutical Services
- Ypsomed
